How to Manage Controlled Substance Investigational Products in Clinical Trials

Published on 21/12/2025

Best Practices for Managing Controlled Substance Investigational Products in Clinical Trials

Managing controlled substances in clinical trials requires an advanced level of oversight, security, and compliance. These substances—often Schedule I-IV drugs—carry a high risk of abuse or diversion and are strictly regulated by national authorities such as the USFDA and the Drug Enforcement Administration (DEA). This tutorial outlines how to securely manage controlled substance investigational products (IPs) during clinical trials, from receipt through reconciliation and destruction.

Table of Contents

What Qualifies as a Controlled Substance IP?

Controlled substances are drugs classified under national regulatory schedules due to their potential for abuse and dependence. In clinical research, opioids, stimulants, sedatives, cannabinoids, and some antidepressants often fall under this category.

Examples:

Schedule II: Morphine, Oxycodone
Schedule III: Buprenorphine
Schedule IV: Diazepam, Lorazepam
Schedule I (research only): Psilocybin, LSD (under special exemptions)

Regulatory Requirements for Controlled IPs:

Clinical trials involving controlled substances must comply with stringent regulations concerning import/export, storage, handling, accountability, and documentation. Agencies like CDSCO in India and MHRA in the UK enforce these protocols strictly.

Key Requirements:

Licensing for sites and investigators to store/dispense controlled substances
Use of tamper-evident, restricted-access storage areas (e.g., narcotic vaults)
Detailed tracking

of every unit from receipt to destruction

Real-time documentation and deviation reporting

Receiving and Verifying Controlled IP Shipments:

Controlled IPs must be shipped via secure, licensed couriers and received by authorized personnel only. Upon receipt, the shipment must be inspected and verified immediately against the shipping manifest.

Receiving Checklist:

Inspect external packaging for tampering
Match shipment to delivery documentation
Log receipt in site-specific controlled substance inventory form
Securely transfer to restricted storage
Notify sponsor and complete chain-of-custody records

Storage and Security Measures:

Controlled IPs must be stored in DEA-compliant vaults or double-locked cabinets with limited access. Temperature and humidity monitoring are also required where applicable.

Secure Storage Protocols:

24/7 video surveillance and intrusion detection systems
Access restricted to trained, authorized staff
Storage logs including access time, personnel, and reason
Backup power to maintain environmental controls

To support storage documentation compliance, refer to validated SOPs at Pharma SOP documentation.

Dispensation and Tracking:

Each unit of a controlled substance dispensed must be recorded with exact details of who received it, when, and under what conditions. Double verification and witness logs are often required.

Required Documentation:

Subject ID, visit number, and dosage details
Lot/batch number and expiry date
Name and signature of dispenser and witness
Reason for return, if applicable

Accountability and Reconciliation Procedures:

Accountability logs must provide a complete, real-time record of IP usage. Reconciliation must occur periodically and during study closeout to account for every unit received, dispensed, returned, or destroyed.

For structured reconciliation procedures, consult Stability Studies for handling sensitive products.

Reconciliation Process:

Cross-check physical inventory with digital or manual logs
Investigate and report any discrepancies
Document final disposition (used, returned, destroyed)
Update the Trial Master File (TMF) with signed reconciliation summary

Destruction of Controlled Substances:

Destruction must be performed by licensed vendors with documented procedures. In some regions, on-site destruction must be witnessed by regulatory representatives or notary officials.

Steps for IP Destruction:

Request and obtain sponsor authorization
Prepare Destruction Form with IP details
Schedule incineration or chemical disposal with licensed provider
Witness and document the destruction event
Archive Certificate of Destruction in the TMF

Packaging and shipment of returned controlled IPs must comply with GMP documentation for chain-of-custody maintenance.

Training and Quality Oversight:

All staff involved in handling controlled substances must receive documented training specific to local laws, sponsor SOPs, and trial protocols. QA audits should assess adherence to procedures and adequacy of documentation.

Training Topics Include:

Controlled substance classification and risk
Secure storage and access protocols
Chain of custody and documentation
Deviation and discrepancy reporting

Audit Readiness and Regulatory Inspections:

Regulatory agencies can conduct unannounced audits for controlled substance trials. Sites must be audit-ready with complete logs, training records, and deviation reports.

Audit Preparation Checklist:

Daily vault access logs
Inventory reconciliation reports
Training logs and certificates
Return and destruction documentation
Deviation forms with CAPA, if applicable

Conclusion:

Managing controlled substance investigational products requires stringent control over every step in the trial lifecycle. From specialized storage and restricted access to thorough documentation and reconciliation, clinical teams must demonstrate accountability and regulatory compliance at all times. Following these best practices ensures ethical, legal, and scientific integrity throughout the study.